Levamlodipine besylate (0.1, 0.5 mg/kg, once daily; 8 weeks; p.o.) can restore hippocampal Ca2+/CaM dependent protein kinase II (CaMKII) and alleviate hippocampal dependent spatial cognitive impairment in vascular dementia mice[1].
Levamlodipine besylate (1 mg/kg, once daily; 16 weeks; p.o.) can lower blood pressure and protect organs in spontaneously hypertensive rats[3].
| Animal Model: | Spontaneously hypertensive rats (SHR)[3]. |
| Dosage: | 1 mg/kg |
| Administration: | Oral gavage (p.o.); once daily; 16 weeks |
| Result: | Reduced systolic blood pressure (SBP) and diastolic blood pressure (DBP), reduced heart and aortic hypertrophy, increased kidney weight to prevent kidney atrophy. |
| Animal Model: | VaD mice model of right unilateral common carotid arteries occlusion (rUCCAO)[1]. |
| Dosage: | 0.1, 0.5 mg/kg |
| Administration: | Oral gavage (p.o.); once daily; 8 weeks |
| Result: | Recovered phosphorylated CaMKII (Thr286) levels in the hippocampus and improved cognitive impairment in mice. |
